Showing results (1351-1360 of 1,430) with videos related to
Sort By:
Pageof 143
Annals of Translational Medicine|May 14, 2021
Geriatric nutritional risk index as an independent prognostic factor in locally advanced nasopharyngeal carcinoma treated using radical concurrent chemoradiotherapy: a retrospective cohort studyQing-Nan Tang, Hui-Zhi Qiu, Xiao-Qing Sun, et al.Oral Oncology|May 1, 2018
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinomaMei Lin, Rui You, You-Ping Liu, et al.Journal of the National Cancer Institute|November 8, 2011
Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trialQiu-Yan Chen, Yue-Feng Wen, Ling Guo, et al.BMC Cancer|August 25, 2017
Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control studyYang Li, Qiu-Yan Chen, Lin-Quan Tang, et al.The Lancet. Respiratory Medicine|May 23, 2022
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJing-Xin Li, Shi-Po Wu, Xi-Ling Guo, et al.Journal of Hematology & Oncology|January 5, 2020
Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinomaQian Zhu, Ai-Lin Zhong, Hao Hu, et al.Journal of Cancer|May 29, 2018
The prognosis of neck residue nasopharyngeal carcinoma (NPC) patients: results from a case-cohort studySai-Lan Liu, Lin-Quan Tang, Qiu-Yan Chen, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNALi-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, et al.Signal Transduction and Targeted Therapy|July 16, 2021
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trialsFan-Yue Meng, Fan Gao, Si-Yue Jia, et al.Genomics, Proteomics & Bioinformatics|August 23, 2025
Duckweed Evolution: from Land back to WaterYang Fang, Xueping Tian, Yanling Jin, et al.Pageof 143